Show simple item record

dc.contributor.authorFife, Ken_US
dc.contributor.authorHerd, Ren_US
dc.contributor.authorLalondrelle, Sen_US
dc.contributor.authorPlummer, Ren_US
dc.contributor.authorStrong, Aen_US
dc.contributor.authorJones, Sen_US
dc.contributor.authorLear, JTen_US
dc.date.accessioned2018-02-19T16:29:04Z
dc.date.issued2017-01en_US
dc.identifier.citationFuture Oncology, 2017, 13 (2), pp. 175 - 184en_US
dc.identifier.issn1479-6694en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1313
dc.identifier.eissn1744-8301en_US
dc.identifier.doi10.2217/fon-2016-0296en_US
dc.description.abstractBasal cell carcinomas are the most common form of skin cancer. Some develop into advanced cases not suitable for standard therapy. Vismodegib is the first-in-class oral hedgehog pathway inhibitor (which is dysregulated in 90% of basal cell carcinomas), and has demonstrated efficacy for advanced disease in clinical trials. An UK expert panel met to discuss management strategies for adverse events associated with vismodegib (most commonly taste disturbances, muscle cramps and alopecia). Managing patient expectations and implementing treatment breaks were considered important strategies. Quinine was useful to alleviate muscle cramps. For taste disturbances, food swaps alongside dietician referral were suggested. The experts concluded that these common adverse events can be successfully managed to allow optimum treatment duration of vismodegib.en_US
dc.formatPrint-Electronicen_US
dc.format.extent175 - 184en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectHumansen_US
dc.subjectCarcinoma, Basal Cellen_US
dc.subjectSkin Neoplasmsen_US
dc.subjectAnilidesen_US
dc.subjectPyridinesen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectDisease Managementen_US
dc.subjectClinical Trials as Topicen_US
dc.subjectDrug-Related Side Effects and Adverse Reactionsen_US
dc.titleManaging adverse events associated with vismodegib in the treatment of basal cell carcinoma.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.2217/fon-2016-0296en_US
rioxxterms.licenseref.startdate2017-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfFuture Oncologyen_US
pubs.issue2en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Gynaecological Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Gynaecological Cancer/Gynaecological Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume13en_US
pubs.embargo.termsNot knownen_US
icr.researchteamGynaecological Canceren_US
dc.contributor.icrauthorLalondrelle, Susanen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record